5.2 ICFR - material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period
(a.)a description of the material weakness;
(b.)the impact of the material weakness on the issuer's financial reporting and its ICFR; and
(c.)the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.
5.3 Limitation on scope of design: N/A
6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on July 1, 2026 and ended on September 30, 2026 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
Dated November 16, 2026.
(signed) "Kyle Kazan"
Kyle Kazan
Chief Executive Officer